Press Releases

Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases

GeneXpert Systems and Xpert Tests Expected to Enhance Efficiency of Clinical Trials

SUNNYVALE, Calif., Jan. 13, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients. These tests will be used to help identify patients for MedImmune's MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use of biologics in preventing ventilator associated pneumonia (VAP) infections in intensive-care-unit (ICU) patients.

USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug- Resistant Tuberculosis

SUNNYVALE, Calif., Jan. 7, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has signed a Memorandum of Understanding (MOU) representing the intention of the company, working with the United States Agency for International Development (USAID), to support the White House's National Action Plan for Combating Multidrug-Resistant Tuberculosis. The National Action Plan identifies critical interventions to be taken by United States Government agencies and partners to reverse the worldwide spread of multidrug-resistant (MDR) tuberculosis (TB). The MOU is expected to be followed by a Collaborative Agreement between Cepheid and USAID setting out the details of this cooperation.

Cepheid Announces Distribution Agreement with Henry Schein

SUNNYVALE, Calif., Jan. 4, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced an agreement with Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc., for the distribution of its GeneXpert® System and menu of 17 Xpert® tests spanning healthcare associated infections, critical infectious disease, and sexual health.